Harpoon Medical, a medical device company focused on minimally-invasive, beating-heart, mitral valve repair, announced that ten patients with severe degenerative mitral valve disease are now enrolled in its ongoing Early Feasibility Study at two clinical study sites in Europe.
The company will showcase the results of the Early Feasibility Study, including a 100 % procedural success rate, over 850 total implant days and echocardiographic data on the first two patients with trace MR during their six-month follow up visit, at the upcoming 2015 Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco, CA on October 12, 2015.
Harpoon also announced that it has received investments for $1.4 million of convertible debt as part of a two million dollar bridge financing expected to be completed before the end of the month.
The funds will be used to support the ongoing Early Feasibility Study and start a larger clinical trial, scheduled to begin enrolling patients before the end of the year, to support CE Mark approval.
"Conventional mitral valve surgery performed by a skilled surgeon is safe and effective, but it is an invasive procedure with significant morbidity," said James S. Gammie, M.D., founder of Harpoon Medical and Chief of Cardiac Surgery at the University Of Maryland School Of Medicine.